ArticleNeuropsychiatric disease and treatment2012
5-HTP efficacy and contraindications.
Article in Neuropsychiatric disease and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Promoting cognitive health through the nexus of gut microbiota and dietary phytochemicals.Frontiers in nutrition · 2025Review
- Beyond the Brain: Perinatal Exposure of Rats to Serotonin Enhancers Induces Long-Term Changes in the Jejunum and Liver.Biomedicines · 2024Article
- Metabolic engineering of Escherichia coli for efficient production of L-5-hydroxytryptophan from glucose.Microbial cell factories · 2022Article
- Effects of Duodenal 5-Hydroxytryptophan Perfusion on Melatonin Synthesis in GI Tract of Sheep.Molecules (Basel, Switzerland) · 2021Article
- CoMNRank: An integrated approach to extract and prioritize human microbial metabolites from MEDLINE records.Journal of biomedical informatics · 2020Article
- Advances in Nutritional Epigenetics-A Fresh Perspective for an Old Idea. Lessons Learned, Limitations, and Future Directions.Epigenetics insights · 2020Article
- Article
- Serum Metabolomics Identifies Altered Bioenergetics, Signaling Cascades in Parallel with Exposome Markers in Crohn's Disease.Molecules (Basel, Switzerland) · 2019Article
- Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome.The American journal of case reports · 2017Article
- Article
- Parkinson's disease managing reversible neurodegeneration.Neuropsychiatric disease and treatment · 2016Article
- Parkinson's disease-associated melanin steal.Neuropsychiatric disease and treatment · 2014Article
Corrections and comments
- Retraction · 2021-03-03Cites Retracted Work · Concerns/Issues about Data · Concerns/Issues about Image · Investigation by Journal/Publisher · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2020-04-23Concerns/Issues about Referencing/Attributions · Conflict of Interest · Investigation by Journal/Publisher · Upgrade/Update of Prior Notice(s) ·
- Expression of concern
- Retracted
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-5-hydroxytryptophan (5-HTP) is the immediate precursor of serotonin. It is readily synthesized into serotonin without biochemical feedback. This nutrient has a large and strong following who advocate exaggerated and inaccurate claims relating to its effectiveness in the treatment of depression and a number of other serotonin-related diseases. These assertions are not supported by the science. Under close examination, 5-HTP may be contraindicated for depression in some of the very patients for whom promoters of 5-HTP advocate its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.